Topiramate enhances the risk of valproate-associated side effects in three children.
about
Molecular and therapeutic potential and toxicity of valproic acidAnticonvulsant drugs and hematological disease.Case report of valproate-induced hypothermia in a patient with schizoaffective disorder.Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapyValproic Acid and topiramate induced hyperammonemic encephalopathy in a patient with normal serum carnitineTopiramate in the treatment of partial and generalized epilepsy.Valproic Acid-induced hyperammonemia in the elderly: a review of the literatureEncephalopathy in an infant with infantile spasms: possible role of valproate toxicity.Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.Topiramate increases the risk of valproic acid-induced encephalopathy.Topiramate-induced hyperammonemic encephalopathy in a patient with mental retardation: A case report and review of the literaturePharmacokinetics and safety of adjunctive topiramate in infants (1-24 months) with refractory partial-onset seizures: a randomized, multicenter, open-label phase 1 study.Valproate-associated reversible encephalopathy in a 3-year-old girl with Pallister-Killian syndrome.Intentional topiramate ingestion in an adolescent female.Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report.Risk factors for hyperammonemia in pediatric patients with epilepsy.Recurrent Admissions for Hypothermia From Concomitant Topiramate and Phenobarbital: A Case Report.Selecting Rational Drug Combinations in Epilepsy.
P2860
Q21296867-071CF957-C4F7-401D-B8C5-293BFB50AD5FQ33413868-A58754C0-9528-4F53-B96B-F47474CC22DEQ33587050-D259CBEF-18CC-4EE7-B596-8159E9BC2FFAQ36193367-CDCBF1D7-9017-4B95-8EAC-CAC1F546A2C8Q36891327-C8EEA75F-EA4F-4763-BB4E-97CB6D87B9B0Q37129817-DEAA674C-D2B7-44C0-9E05-F3440A64141AQ37317489-4692E6BD-1DF3-46F4-B5BE-7F457EEA13B6Q37711872-BAB32AC0-1CE0-4375-868F-3CA0A481FC68Q38115721-FB571ABC-1FDC-4245-9137-4D9D3DE7267DQ38461708-7758D05E-56DD-4BA7-81E0-03A3DA1FFBCFQ38626912-4FCD5F67-D81A-405C-A357-ECACDABAA2EBQ40267874-25541C08-0F16-4B16-B6DE-B266B0BE77B2Q41360043-44A6EC23-B9F3-41BB-96C3-B94EECF71B2BQ45006201-3C7333C3-6A3B-47E1-9F78-EA3CEAAB3C71Q46407205-558CEE19-A0FB-447C-9A53-02FB36F32859Q46921686-0802FBD7-E969-49CE-8634-E1E548AF8F1EQ47585874-49F7086C-CD78-42AF-A242-33912181F882Q47869836-49F04DD5-FB8C-47CB-B3B3-F87CBCDDCCFA
P2860
Topiramate enhances the risk of valproate-associated side effects in three children.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Topiramate enhances the risk of valproate-associated side effects in three children.
@ast
Topiramate enhances the risk of valproate-associated side effects in three children.
@en
type
label
Topiramate enhances the risk of valproate-associated side effects in three children.
@ast
Topiramate enhances the risk of valproate-associated side effects in three children.
@en
prefLabel
Topiramate enhances the risk of valproate-associated side effects in three children.
@ast
Topiramate enhances the risk of valproate-associated side effects in three children.
@en
P2093
P2860
P1433
P1476
Topiramate enhances the risk of valproate-associated side effects in three children.
@en
P2093
Elke Longin
Martin Teich
Stefan König
P2860
P304
P356
10.1046/J.1528-1157.2002.42401.X
P577
2002-04-01T00:00:00Z